Printer Friendly Version 

Investor Relations Home

Webcast ImageWebcast
Morgan Stanley Global Healthcare Conference (Live)
09/08/14 at 12:00 p.m. ET
Morgan Stanley Global Healthcare Conference
Monday, September 8, 2014  through Wednesday, September 10, 2014 
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
ISIS (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$40.76
Change (%) Stock is Up 0.86 (2.16%)
Volume2,019,315
Data as of 08/29/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
2013 Interactive Annual Report

Recent Press ReleasesMore >>
DateTitle 
08/28/14Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-APOCIII Rx in Patients with FCS
CARLSBAD, Calif., Aug. 28, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS).  FCS is a rare orphan disease, characterized by extremely high triglyceride levels, that affects an estimated 3,000 to 5,000 patients worldwide.  The Phase 3 study of ISIS-APOCIIIRx is a randomized, double-blind, placebo-controlled, six month study in approximately 50 patients diag... 
Printer Friendly Version
08/15/14Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular Atrophy
CARLSBAD, Calif., Aug. 15, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2 million milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA).  The open-label extension study of ISIS-SMNRx is offered to those children with SMA who have completed dosing in Isis' previous studies.  In this study, children with SMA are receiving a 12 ... 
Printer Friendly Version
08/04/14Isis Reports Financial Results and Highlights for Second Quarter 2014
- $40 million in milestone payments from partners drives improved quarterly financial performance - Conference Call Webcast Monday, August 4, 10:30 a.m. ET at www.isispharm.com CARLSBAD, Calif., Aug. 4, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported pro forma net operating income of $1.1 million and a pro forma net operating loss (NOL) of $21.5 million for the three and six months ended June 30, 2014, respectively, compared to an NOL of $5.3 million and $799,... 
Printer Friendly Version
08/01/14Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
-- ENDEAR Trial To Enroll 110 SMA Infants at Sites Globally -- Dosage of First Infant Will Trigger $18 Million Milestone Payment CARLSBAD, Calif., Aug. 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA), the most common genetic cause of infant mortality. Isis plans to dose the first infant in this study within the next few weeks, at which ... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
08/30/14
through
09/03/14
ESC Congress 2014
LocationBarcelonaES
09/03/14
through
09/06/14
2014 International Meeting on Molecular Biology of Hepatitis B Viruses
LocationLos Angeles, CA
09/08/14
through
09/10/14
Morgan Stanley Global Healthcare Conference
LocationNew York, NY US
09/09/14
through
09/12/14
High Blood Pressure Research 2014
LocationSan Francisco, CA
09/13/14
through
09/17/14
45th EMGS Annual Meeting
LocationOrlando, FL
09/15/14
through
09/19/14
50th EASD Annual Meeting
LocationViennaAT
Primary IR Contact
D. Wade Walke, Ph.D.
Vice President, Corporate Communications and Investor Relations
Isis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010
Phone: 760-603-2331

For more information requests, please visit our Information Request page.

If you are interested in Isis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Online Investor Kit

Quickly download files right from our Investor Relations Web site.

Learn More

Financial Tearsheet

Download a brief overview of Isis.

Learn More

News Feeds

Get the latest.

Subscribe

Receive Isis alerts in your email.

Sign Up